{"id":"zg006","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, ZG006 prevents its interaction with its ligands, PD-L1 and PD-L2, thereby releasing the inhibition of T-cell activation and proliferation, leading to enhanced anti-tumor immune response.","oneSentence":"ZG006 is a monoclonal antibody targeting PD-1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:18.920Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT07231445","phase":"PHASE1","title":"Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2026-03","conditions":"Small Cell Lung Cancer","enrollment":100},{"nctId":"NCT05978284","phase":"PHASE1, PHASE2","title":"Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2023-10-27","conditions":"Small Cell Lung Cancer, Neuroendocrine Carcinoma","enrollment":54},{"nctId":"NCT07038096","phase":"PHASE1, PHASE2","title":"ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2025-09-23","conditions":"Small Cell Lung Cancer, Neuroendocrine Carcinoma","enrollment":350},{"nctId":"NCT07189455","phase":"PHASE3","title":"Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2025-12-12","conditions":"Small-cell Lung Cancer","enrollment":420},{"nctId":"NCT07258121","phase":"PHASE1, PHASE2","title":"Study of ZGGS34 in Participants With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2025-12","conditions":"Solid Tumor","enrollment":400},{"nctId":"NCT06283719","phase":"PHASE1, PHASE2","title":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2024-09-02","conditions":"Small Cell Lung Cancer, Neuroendocrine Cancer","enrollment":265},{"nctId":"NCT06592638","phase":"PHASE1","title":"A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2025-03-31","conditions":"Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07024277","phase":"PHASE2","title":"Study of ZG006 in Participants With Neuroendocrine Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2025-08","conditions":"Neuroendocrine Prostate Cancer","enrollment":60},{"nctId":"NCT06440057","phase":"PHASE1, PHASE2","title":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.","status":"RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2024-08-29","conditions":"Neuroendocrine Carcinoma","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ZG006","genericName":"ZG006","companyName":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","companyId":"suzhou-zelgen-biopharmaceuticals-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"ZG006 is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}